Results 11 to 20 of about 5,946,067 (288)

Zoledronic acid induces ferroptosis by reducing ubiquinone and promoting HMOX1 expression in osteosarcoma cells

Frontiers in Pharmacology, 2023
Aims: Ferroptosis plays important roles in tumorigenesis and cancer therapy. Zoledronic acid is known to inhibit the activity of farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway.
Tianhao Ren, Ju Huang, Wei Sun, Guangze Wang, Yuwen Wu, Zewei Jiang, Yingshuai Lv, Guang Wu, Jiawei Cao, Min Liu, Haihua Gu   +10 more
doaj   +2 more sources

How zoledronic acid improves osteoporosis by acting on osteoclasts

Frontiers in Pharmacology, 2022
Osteoporosis is called a silent disease, because it is difficult to detect until comprehensive examinations for osteoporosis are performed or osteoporotic fractures occur.
Biao Wang, Yi Zhan, Yi Zhan, Liang Yan, Dingjun Hao   +4 more
doaj   +2 more sources

Comparison of Denosumab and Zoledronic acid as neoadjuvant therapy in patients with giant cell tumor of bone

Journal of Orthopaedic Surgery, 2021
Objectives: Both Zoledronic acid and denosumab have been utilized in neo-adjuvant setting for facilitating surgery and downsizing the lesion in Giant cell tumor (GCT).
Himanshu Kanwat, Roshan Banjara, Venkatesan Sampath Kumar, Abdul Majeed, Shivanand Gamnagatti, Shah Alam Khan   +5 more
doaj   +2 more sources

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Lancet, The, 2016
Summary Background Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design.
Nicholas D. James, Nicholas D. James, M. Sydes, N. Clarke, M. Mason, D. Dearnaley, M. Spears, A. Ritchie, C. Parker, J. Russell, G. Attard, J. Bono, W. Cross, Robert Jones, G. Thalmann, C. Amos, D. Matheson, R. Millman, M. Alzouebi, S. Beesley, A. Birtle, S. Brock, R. Cathomas, P. Chakraborti, S. Chowdhury, A. Cook, T. Elliott, J. Gale, S. Gibbs, J. Graham, J. Hetherington, R. Hughes, R. Laing, F. McKinna, D. McLaren, J. O’Sullivan, O. Parikh, C. Peedell, A. Protheroe, A. Robinson, N. Srihari, R. Srinivasan, J. Staffurth, S. Sundar, S. Tolan, D. Tsang, J. Wagstaff, M. Parmar   +47 more
semanticscholar   +3 more sources

Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cells. [PDF]

PLoS ONE, 2015
While targeted therapy brought a new era in the treatment of BRAF mutant melanoma, therapeutic options for non-BRAF mutant cases are still limited. In order to explore the antitumor activity of prenylation inhibition we investigated the response to ...
Tamás Garay, István Kenessey, Eszter Molnár, Éva Juhász, Andrea Réti, Viktória László, Anita Rózsás, Judit Dobos, Balázs Döme, Walter Berger, Walter Klepetko, József Tóvári, József Tímár, Balázs Hegedűs   +13 more
doaj   +5 more sources

Zoledronic Acid Is Not Equally Potent on Osteoclasts Generated From Different Individuals

JBMR Plus, 2020
Zoledronic acid is a bisphosphonate commonly used to treat bone diseases such as osteoporosis and cancer‐induced bone disease. Patients exhibit a variable sensitivity to zoledronic acid; the underlying explanation for this remains unclear.
Anaïs M J Møller, Jean‐Marie Delaisse, Jacob B Olesen, Troels Bechmann, Jonna S Madsen, Kent Søe   +5 more
doaj   +2 more sources

Cost-Effectiveness of Zoledronic Acid Versus Oral Alendronate for Postmenopausal Osteoporotic Women in China

Frontiers in Pharmacology, 2020
ObjectiveThis study aims to estimate the cost-effectiveness of yearly intravenous zoledronic acid treatment versus weekly oral alendronate for postmenopausal osteoporotic women in China.MethodsWe used a Markov microsimulation model to compare the cost ...
Ruxu You, Yu Zhang, David Bin-Chia Wu, Jinyu Liu, Xinyu Qian, Nan Luo, Takahiro Mori, Takahiro Mori, Takahiro Mori   +8 more
doaj   +2 more sources

Breast-cancer adjuvant therapy with zoledronic acid [PDF]

New England Journal of Medicine, 2011
Background: Data suggest that the adjuvant use of bisphosphonates reduces rates of recurrence and death in patients with early-stage breast cancer. We conducted a study to determine whether treatment with zoledronic acid, in addition to standard adjuvant
Barrett-Lee, Peter J., Bell, Richard, Bundred, Nigel, Burkinshaw, Roger, Cameron, David, Coleman, Robert E., Davies, Claire, Dodwell, David, Gaunt, Claire, Gil, Miguel, Gregory, Walter, Grieve, Robert J., Hiley, Victoria, Houston, Stephen J., Keane, Maccon, Marshall, Helen, Peterson, Jennifer, Pugh, Julia, Rea, Una, Ritchie, Diana   +19 more
core   +3 more sources

Zoledronic acid inhibits the growth of leukemic MLL-AF9 transformed hematopoietic cells

Heliyon, 2020
A leukemic in vitro model produced by transducing Cord Blood derived-hematopoietic CD34+ cells with the MLL-AF9 translocation resulting in the oncogenic fusion protein, is used to assess for sensitivity to Zoledronic acid.
Emanuela Chiarella, Bruna Codispoti, Annamaria Aloisio, Emanuela G. Cosentino, Stefania Scicchitano, Ylenia Montalcini, Daniela Lico, Giovanni Morrone, Maria Mesuraca, Heather M. Bond   +9 more
doaj   +2 more sources

Fanconi Syndrome After a Single Exposure to Intravenous Zoledronic Acid [PDF]

Clinical Case Reports
Bisphosphonates are commonly used to reduce fracture risk in patients with osteoporosis, in those with malignant metastatic bone disease and for treatment of malignant hypercalcaemia.
Rita Deb, Muhammad Elboghdady, Alvin Shrestha   +2 more
doaj   +2 more sources